Takeda TAK-881 Wins Pivotal Phase 2/3 in PID
Takeda announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease previously treated with immunoglobulin therapy, met its primary endpoint demonstrating pharmacokinetic comparability to HyQvia. The trial evaluated TAK-881…
